Crcdc-Cvl
Tours, 37000, France
NCT Number: NCT06032338
The effect of mailing FIT with the invitation on participation and colonoscopy rates will be evaluated in a randomized controlled trial conducted in the Centre-Val de Loire (CVL) region, involving 64,000 people from the population eligible for colorectal cancer population-based organised screening program (CRC-PBOSP).
In the "C" control group, invitations, test delivery and reminders will be carried out in accordance with the CRC-PBOSP rules at the time of the study.
Intervention group "B" will evaluate two experimental modes of invitation with direct home mailing of the test:
* Method "B1": invitation with test sent to home without prior information letter * Method "B2": information letter followed by invitation with test sent home, designed to optimize participation by first-time subjects (aged 50-51) invited to the CRC-PBOSP for the first time.
Ancillary studies will focus 1/ on acceptability of this intervention (qualitative study on a few general practitioners, gastroenterologists and invitees), 2/ on social and geographical inequalities of participation on a subsample of individuals included in EXPEDIT study using ecological indices (EDI, SCALE).
This study is active but is not currently recruiting participants.
Notify Me50 year–74 year
All sexes
Interventional
Not applicable
Tours, 37000, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Subjects refusing data transmission to research team will be excluded from statistical analyses.
The invitation to CRC-PBOSP will only contain informations on how to get the screening test.
The invitation to CRC-PBOSP will contain the CRC screening test.
An information letter will be sent to future invitees a few weeks before the invitation, to announce the mailing of the CRC screening kit.
Time frame: 16 months after the invitation
Rate of FIT sent to laboratory for analysis within 16 of months of invitation among invitees.
Time frame: 6 months after the positive FIT
Rate of Colonoscopy within 6 months after positive FIT among invitees with a positive FIT
Time frame: 24 months after invitation
Rate of FIT sent to laboratory for analysis within 24 of months of invitation among invitees.
Time frame: 24 months after invitation
Time to screening participation within 24 months of invitation among invitees
Time frame: 12 months after the positive test
Rate of Colonoscopy within 12 months after positive FIT among invitees with a positive FIT
Time frame: 12 months after the positive test
Time from FIT to colonoscopy within 12 months of positive FIT among invitees with a positive FIT
Time frame: 12 months after the positive test
Rate of colorectal cancer or advanced neaplasia in invitees with a positive FIT
Time frame: 16 months after invitation
Rate of FIT sent to laboratory for analysis within 16 of months of invitation among first invitees (50-51 yrs-old)
Time frame: 24 months
Costs of CSC-PBOSP from invitation to colonoscopy when necessary
University Hospital, Caen
Other
EXPérimentation d'Envoi Postal DIrect à Domicile du kiT de dépistage du Cancer Colorectal Sans Commande préalable [Trial of Direct Home Delivery of Colorectal Cancer Screening Kit Without Pre-ordering]
Acronym: EXPEDIT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06305247
Carcinoma, Carcinoma, Squamous Cell
Los Angeles, California, United States
View Trial DetailsNCT05464030
Colonic Diseases, Colorectal Cancer
Encinitas, California, United States
View Trial DetailsNCT04117087
Colonic Diseases, Colonic Neoplasms
Baltimore, Maryland, United States
View Trial DetailsNCT04258137
Bronchial Neoplasms, Carcinoma, Bronchogenic
Bayonne, France
View Trial Details